Publication | Closed Access
Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer (AOC): Results of an international intergroup trial (AGO-OVAR16).
65
Citations
0
References
2013
Year
Cancer ManagementGynecologyPathologyPharmacotherapyGynecology OncologyOvarian CancerOncologyMetronomic TherapyPhase Iii TrialClinical TrialsCancer Cell BiologyClinical OncologyRadiation OncologyCancer ResearchMolecular OncologyFinal TextHealth SciencesAsco Daily NewsCancer TreatmentMalignant DiseaseTumoral PathologyPazopanib Versus PlaceboInternational Intergroup TrialMedicine
LBA5503 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Saturday, June 1, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.